Novo Nordisk's diabetes drug Ozempic slashed the risk of kidney disease progression in trial

Novo Nordisk's diabetes drug Ozempic slashed the risk of kidney disease progression in trial


This picture taken on October 23, 2023, shows Ozempic medication boxes, an injectable antidiabetic drug, in a pharmacy in Riedisheim, eastern France. 

Sebastien Bozon | Afp | Getty Images

Novo Nordisk‘s blockbuster drug Ozempic cut the risk of kidney disease progression and related health complications in diabetic patients, according to initial late-stage trial results released Tuesday. 

Ozempic specifically lowered the risk of kidney disease progression, major cardiac events and death by 24% in diabetic patients with chronic kidney disease compared to a placebo. 

The results add to the growing evidence that the highly popular injection and similar drugs for weight loss have broader health benefits for patients beyond treating Type 2 diabetes and helping them shed pounds. Those treatments skyrocketed in popularity over the last year despite their mixed insurance coverage and hefty price tags.

Novo Nordisk said it will present full data from the study later this year. The company also noted that it would file for an expanded approval of Ozempic based on the data in both the U.S. and Europe.

Chronic kidney disease would be a big additional treatment opportunity for Ozempic: Roughly 40% of people with diabetes also have the condition. The disease involves a gradual loss of kidney function.

Notably, the Danish company ended the trial in October – a year earlier than expected – in response to positive results.

The trial, called FLOW, first started in 2019 and followed roughly 3,500 patients with diabetes and moderate to severe chronic kidney disease.

The data comes as Novo Nordisk faces increased competition from Eli Lilly and tries to win expanded insurance coverage for its separate weight loss injection, Wegovy.

Last year, a late-stage trial on Wegovy showed that it cut the risk of heart attacks and strokes by 20%. 



Source

Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 20%
Health

Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 20%

The “Wegovy” brand slimming syringe is sold in the Achat pharmacy in Mitte. The “Wegovy” slimming syringe has been available in Germany for a year. Jens Kalaene | Picture Alliance | Getty Images Novo Nordisk on Monday said it is ending its collaboration with Hims & Hers due to concerns about the telehealth company’s sales […]

Read More
Major U.S. health insurers say they will streamline controversial process for approving care
Health

Major U.S. health insurers say they will streamline controversial process for approving care

UnitedHealthcare signage is displayed on an office building in Phoenix, Arizona, on July 19, 2023. Patrick T. Fallon | Afp | Getty Images Health plans under major U.S. insurers said Monday they have voluntarily agreed to speed up and reduce prior authorizations – a process that is often a major pain point for patients and […]

Read More
Healthy Returns: What to know about the FDA’s plan to speed up some drug reviews
Health

Healthy Returns: What to know about the FDA’s plan to speed up some drug reviews

FILE PHOTO: The headquarters of the U.S. Food and Drug Administration (FDA) is seen in Silver Spring, Maryland November 4, 2009.  Jason Reed | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The Food […]

Read More